Monash IVF shares plunge after second incorrect embryo transfer
Make us a preferred source
Make us a preferred source on Google
The news: Shares in Monash IVF plummeted on Tuesday morning after the fertility clinic provider said it mistakenly transferred a patient’s own embryo back to themself, instead of their partner's embryo — the second mix-up it has revealed this year.
The numbers: Shares in Monash IVF had plunged 21.5% to $0.58 at 10:30am AEST.
The context: Monash IVF said in a statement that at its Clayton laboratory in Melbourne on 5 June, it incorrectly transferred a patient’s own embryo back to the same patient, but the treatment plan involved transferring the embryo of the patient’s partner.
The incident has been disclosed to assisted reproductive technology regulators, the Reproductive Accreditation Committee certifying body and the Victorian Health Regulator.
The company said in a statement to the ASX that it will immediately implement “interim additional verification processes and patient confirmation safeguards over and above normal practice and electronic witness systems”.
It added that while electronic witness systems were already being rolled out, manual witnessing is still required in some instances.
No change has been made to Monash IVF's profit guidance from 20 May and the incident is within the scope of the company's insurance coverage.
An internal investigation has commenced, while the scope of an ongoing independent review, led by Fiona McLeod, into a separate incident that took place at a Brisbane clinic has been extended to include the latest mix-up.
Two months ago, Monash IVF confirmed another incident in which it had transferred someone else’s frozen embryo into a patient who subsequently gave birth. The company says it became aware of the incident, which took place in 2023, in February 2025.
An internal investigation blamed the incident, which took place at a Brisbane clinic, on human error.
The source: ASX
